Non-Small Cell Lung Cancer Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca, AbbVie

Posted on
by

Non-Small Cell Lung Cancer Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca, AbbVie
“Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the 7MM.

DelveInsight’s “Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Non-Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Small Cell Lung Cancer Market Forecast

 

Some of the key facts of the Non-Small Cell Lung Cancer Market Report: 

  • The Non-Small Cell Lung Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In January 2023, Novocure announced that the LUNAR study, assessing the safety and effectiveness of Tumor Treating Fields (TTFields) alongside standard treatments for stage 4 non-small cell lung cancer (NSCLC) after progression on or following platinum-based therapy, successfully achieved its primary goal.
  • In December 2022, The FDA in the United States has granted accelerated approval to Mirati’s Krazati (adagrasib), providing a targeted therapy for adult individuals diagnosed with KRAS-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
  • In 2020, there were 227,875 lung cancer incident cases in the US, of which 85%, or 193,694 people, had non-small cell lung cancer. The highest number of NSCLC cases were found in Germany among the five European nations
  • Additionally, Japan will be responsible for around 117,752 cases in 2020. The United States was expected to have the largest number of NSCLC cases
  • The prevalence of EGFR-NSCLC is highest in the United States, where 34% of the population overall has EGFR-mutated NSCLC in the 7MM (as of 2020). The United Kingdom, France, Italy, and Spain were the next five European nations in order of incident population of NSCLC, with Germany having the highest incident population, estimated to be over 29%
  • Key Non-Small Cell Lung Cancer Companies: AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Merck Sharp & Dohme LLC, Arcus Biosciences, Inc., Ono Pharmaceutical Co. Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others
  • Key Non-Small Cell Lung Cancer Therapies: Telisotuzumab Vedotin, Ensartinib (X-396), SAR408701, Hyleukin-7 (NT-I7;Efineptakin Alfa), Avelumab (Bavencio), Sitravatinib, Trastuzumab deruxtecan, DS-1062a, Durvalumab, Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Domvanalimab, ONO-4538, M7824, Retifanlimab, Lenvatinib, and others
  • The Non-Small Cell Lung Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Small Cell Lung Cancer pipeline products will significantly revolutionize the Non-Small Cell Lung Cancer market dynamics.

 

Non-Small Cell Lung Cancer Overview

About 85% of all cases of lung cancer are NSCLC, making it the most prevalent kind. In contrast to SCLC, which has much smaller cells under the microscope, NSCLC metastasizes to other organs more slowly.

 

Get a Free sample for the Non-Small Cell Lung Cancer Market Report: 

https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market

 

Non-Small Cell Lung Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Non-Small Cell Lung Cancer Epidemiology Segmentation:

The Non-Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Non-Small Cell Lung Cancer
  • Prevalent Cases of Non-Small Cell Lung Cancer by severity
  • Gender-specific Prevalence of Non-Small Cell Lung Cancer
  • Diagnosed Cases of Episodic and Chronic Non-Small Cell Lung Cancer

 

Download the report to understand which factors are driving Non-Small Cell Lung Cancer epidemiology trends @ Non-Small Cell Lung Cancer Epidemiology Forecast

 

Non-Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers Non-Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non-Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Non-Small Cell Lung Cancer Therapies and Key Companies

  • Telisotuzumab Vedotin: AbbVie
  • Ensartinib (X-396): Xcovery
  • SAR408701: Sanofi
  • Hyleukin-7 (NT-I7;Efineptakin Alfa): NeoImmune Tech
  • Avelumab (Bavencio): Merck KGaA and Pfizer
  • Sitravatinib: Mirati Therapeutics
  • Trastuzumab deruxtecan: AstraZeneca
  • DS-1062a: Daiichi Sankyo, Inc.
  • Durvalumab: Parexel
  • Sacituzumab Govitecan-hziy (SG): Gilead Sciences
  • Pembrolizumab: Merck Sharp & Dohme LLC
  • Domvanalimab: Arcus Biosciences, Inc.
  • ONO-4538: Ono Pharmaceutical Co. Ltd
  • M7824: EMD Serono
  • Retifanlimab: Incyte Corporation
  • Lenvatinib: Eisai Inc.

 

To know more about Non-Small Cell Lung Cancer companies working in the treatment market, visit @ Non-Small Cell Lung Cancer Clinical Trials and Therapeutic Assessment 

 

Non-Small Cell Lung Cancer Market Drivers

  • Premium-price targeted agents with better clinical profile and expansion of therapies in the first-line expected to drive the growth of NSCLC market
  • The development of therapies targeting specific mutations are expected to dominate the upcoming market

 

Non-Small Cell Lung Cancer Market Barriers

  • Potential for premium pricing of emerging therapies by showing an edge over current therapies Uptake of potential emerging therapies with better clinical profile, specificity towards mutations occurs in NSCLC and therapies to overcome resistance expected to be fast

 

Scope of the Non-Small Cell Lung Cancer Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Non-Small Cell Lung Cancer Companies: AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Merck Sharp & Dohme LLC, Arcus Biosciences, Inc., Ono Pharmaceutical Co. Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others
  • Key Non-Small Cell Lung Cancer Therapies: Telisotuzumab Vedotin, Ensartinib (X-396), SAR408701, Hyleukin-7 (NT-I7;Efineptakin Alfa), Avelumab (Bavencio), Sitravatinib, Trastuzumab deruxtecan, DS-1062a, Durvalumab, Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Domvanalimab, ONO-4538, M7824, Retifanlimab, Lenvatinib, and others
  • Non-Small Cell Lung Cancer Therapeutic Assessment: Non-Small Cell Lung Cancer current marketed and Non-Small Cell Lung Cancer emerging therapies
  • Non-Small Cell Lung Cancer Market Dynamics: Non-Small Cell Lung Cancer market drivers and Non-Small Cell Lung Cancer market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Non-Small Cell Lung Cancer Unmet Needs, KOL’s views, Analyst’s views, Non-Small Cell Lung Cancer Market Access and Reimbursement 

 

Discover more about therapies set to grab major Non-Small Cell Lung Cancer market share @ Non-Small Cell Lung Cancer Treatment Market 

 

Table of Contents 

1. Non-Small Cell Lung Cancer Market Report Introduction

2. Executive Summary for Non-Small Cell Lung Cancer

3. SWOT analysis of Non-Small Cell Lung Cancer

4. Non-Small Cell Lung Cancer Patient Share (%) Overview at a Glance

5. Non-Small Cell Lung Cancer Market Overview at a Glance

6. Non-Small Cell Lung Cancer Disease Background and Overview

7. Non-Small Cell Lung Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Non-Small Cell Lung Cancer 

9. Non-Small Cell Lung Cancer Current Treatment and Medical Practices

10. Non-Small Cell Lung Cancer Unmet Needs

11. Non-Small Cell Lung Cancer Emerging Therapies

12. Non-Small Cell Lung Cancer Market Outlook

13. Country-Wise Non-Small Cell Lung Cancer Market Analysis (2019–2032)

14. Non-Small Cell Lung Cancer Market Access and Reimbursement of Therapies

15. Non-Small Cell Lung Cancer Market Drivers

16. Non-Small Cell Lung Cancer Market Barriers

17.  Non-Small Cell Lung Cancer Appendix

18. Non-Small Cell Lung Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/